EMA has recommended granting a marketing authorisation in the European Union for Icotyde (icotrokinra) for the treatment of moderate-to-severe plaque psoriasis in adults and in adolescents from 12 years of age weighing at least 40 kg.
Note: The applicant for Icotyde is Janssen-Cilag International N.V.
Europa Monitor is a seasoned News Editor with over a decade of experience in journalism. Known for his editorial expertise and commitment to accuracy, Europa Monitor leads teams to deliver high-quality news content.
